Multiple sclerosis (Houndmills, Basingstoke, England) · 2013
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Olsson Tomas, Achiron Anat, Alfredsson Lars, Berger Thomas, Brassat David, Chan Andrew, Comi Giancarlo, Eraksoy Mefkure, Hegen Harald, Hillert Jan, Jensen Poul Erik Hyldgaard, Moiola Lucia, Myhr Kjell-Morten, Oturai Annette, Schippling Sven, Siva Aksel, Sorensen Per Soelberg, Trampe Anne-Kathrin, Weber Thomas, Potts James, Plavina Tatiana, Paes Dominic, Subramanyam Meena, Wiendl Heinz, Dib Hussein, Uren Deniz, Hemmer Bernhard, Buck Dorothea
Аннотация
JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.